$37.29+0.1%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 13, 2026
Just reported
From Nektar Therapeutics's results release of November 12, 2026; its quarterly report has since been filed.
Actual
$9.4M
-20% y/y
-7.4% q/q
Guided
—
No guide given
Actual
-$1.63
Guided
—
No guide given
Actual
-$57.8M
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $9.4M | $11.8M | -20.39% |
| Profit | -$55.7M | -$35.5M | -56.67% |
| Profit per share | -$1.63 | -$1.87 | +12.83% |
| Free Cash Flow | -$72.3M | -$48.9M | -47.99% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Nektar Therapeutics reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Exhibit 99.1 Nektar Therapeutics Announces Third Quarter 2026 Financial Results SAN FRANCISCO, November 12, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today announced its financial results for the third quarter ended September 30, 2026, and provided a business update. Cash and investments in marketable securities on September 30, 2026, were $952.9 million as compared to $245.8 million on December 31, 2025. “This was a pivotal quarter for Nektar as we moved rezpegaldesleukin quickly into Phase 3 development,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar’s lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in atopic dermatitis, alopecia areata, and Type 1 diabetes mellitus. Nektar’s pipeline also includes preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Nektar Therapeutics’s Item 2.02 8-K filed November 12, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.